A Phase 3 registration study of BGE-102
Latest Information Update: 03 Apr 2026
At a glance
- Drugs BGE 102 (Primary)
- Indications Inflammation; Obesity
- Focus Registrational; Therapeutic Use
Most Recent Events
- 03 Apr 2026 New trial record
- 24 Mar 2026 According to BioAge Labs media release, company plan to start the study by the end of 2027.